Illumina

YTD

ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R.

CEO

Jacob Thaysen

CEOJacob Thaysen

Employees

8,600

Employees8,600

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

8,600

Employees8,600

ILMN Key Statistics

Market cap

26.88B

Market cap26.88B

Price-Earnings ratio

31.78

Price-Earnings ratio31.78

Dividend yield

—

Dividend yield—

Average volume

2.05M

Average volume2.05M

High today

$182.84

High today$182.84

Low today

$175.00

Low today$175.00

Open price

$177.94

Open price$177.94

Volume

2.91M

Volume2.91M

52 Week high

$182.84

52 Week high$182.84

52 Week low

$88.00

52 Week low$88.00

Stock Snapshot

The current Illumina(ILMN) stock price is $177.65, with a market capitalization of 26.88B. The stock trades at a price-to-earnings (P/E) ratio of 31.78.

On 2026-06-26, Illumina(ILMN) stock moved within a range of $175.00 to $182.84. With shares now at $177.65, the stock is trading +1.5% above its intraday low and -2.8% below the session's peak.

Trading volume for Illumina(ILMN) stock has reached 2.91M, versus its average volume of 2.05M.

The stock's 52-week range extends from a low of $88.00 to a high of $182.84.

ILMN News

MarketWatch 1d

Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch

...

TipRanks 2d

Illumina price target raised to $145 from $122 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Illumina (ILMN) to $145 from $122 and keeps an Underweight rating on the shares. The firm adjust...

Simply Wall St 2d

How Investors May Respond To Illumina Adding Eli Lilly R&D Chief To Its Board

Illumina, Inc. has expanded its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Office...

Analyst ratings

52%

of 23 ratings

Buy

52.2%

Hold

26.1%

Sell

21.7%

More ILMN News

TipRanks 3d

Illumina Adds Eli Lilly Executive to Board

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.